Virtual Screening Approach for the Identification of New Rac1 Inhibitors
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Rac1 protein is implicated in several events of atherosclerotic plaque development and represents a new potential pharmacological target for cardiovascular diseases. In this paper we describe a pharmacophore virtual screening followed by molecular docking calculations leading to the identification of five new Rac1 inhibitors. These compounds were shown to be more effective than the reference compound NSC23766 in reducing the intracellular levels of Rac1-GTP, thus supporting this approach for the development of new Rac1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rational design and characterization of a Rac GTPase-specific small molecule inhibitor
Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091
Cited by
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?
Vigil, D., Cherfils, J., Rossman, K. L., & Der, C. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2960 · Cited by 819
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
Salo-Ahen, O. M. H., Alanko, I., Bhadane, R., Bonvin, A. M. J. J., Honorato, R. V., Hossain, S., Juffer, A. H., Kabedev, A., Lahtela-Kakkonen, M., Larsen, A. S., et al. (2020) · Processes · doi:10.3390/pr9010071 · Cited by 659
RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis
Bid, H. K., Roberts, R. D., Manchanda, P. K., & Houghton, P. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0164 · Cited by 265
Targeting Rac and Cdc42 GTPases in Cancer
Maldonado, M. D. M., & Dharmawardhane, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0619 · Cited by 237
“1 mmol/L) were selected for further testing and shown to interfere with the Tiam-1/Rac1 interaction (39, 40).”
MethodCharacterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase
Montalvo-Ortiz, B. L., Castillo-Pichardo, L., Hernández, E., Humphries-Bickley, T., De La Mota-Peynado, A., Cubano, L. A., Vlaar, C. P., & Dharmawardhane, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334524 · Cited by 213
Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms
Marei, H., & Malliri, A. (2017) · Small GTPases · doi:10.1080/21541248.2016.1211398 · Cited by 168
“Indeed, a pharmacophore virtual screening approach led to the identification of 5 compounds that selectively inhibit Rac1 GTP loading while not affecting RhoA and Cdc42 activation, 2 of which, ZINC08010136 and ZINC07949036, function through inhibiting Rac1-Tiam1 binding with potencies greater than NSC23766.”
BackgroundInfluentialTargeting Rac and Cdc42 GEFs in Metastatic Cancer
Maldonado, M. D. M., Medina, J. I., Velazquez, L., & Dharmawardhane, S. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00201 · Cited by 122
Modulation of actin dynamics by Rac1 to target cognitive function
Tejada‐Simon, M. V. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13100 · Cited by 76
“Actin dynamics in neurons: link to intellectual disability It is well accepted that members of the Rho family of small GTPases control the assembly and disassembly of the actin cytoskeleton as well as many other cellular activities (Hall 1998, 2005).”
BackgroundInfluentialPharmacological Modulators of Small GTPases of Rho Family in Neurodegenerative Diseases
Guiler, W., Koehler, A., Boykin, C., & Lu, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661612 · Cited by 51
Murray, D. W., Didier, S., Chan, A., Paulino, V, Van Aelst, L., Ruggieri, R., Tran, N. L., Byrne, A. T., & Symons, M. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.39 · Cited by 39
“Moreover, the small molecule GEF inhibitor space is continuing to expand and a number of inhibitors have been successfully developed (Bouquier et al, 2009; Evelyn et al, 2009; Ferri et al, 2009; Shang et al, 2013).”
BackgroundTargeting Small GTPases and Their Prenylation in Diabetes Mellitus
Gendaszewska-Darmach, E., Garstka, M. A., & Błażewska, K. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00410 · Cited by 35
Metadata
- Authors
- Ferri, N., Corsini, A., Bottino, P., Clerici, F., & Contini, A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-06-15
- Volume
- 52
- Issue
- 14
- Pages
- 4087-4090
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2018631917
- Cited by
- 100
- References
- 1
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.